MétaCan
Menu
Back to cohort
Record W4366156895 · doi:10.1016/j.esmoop.2023.101214

Prognostic value of intrinsic subtypes in hormone-receptor-positive metastatic breast cancer: systematic review and meta-analysis

2023· review· en· W4366156895 on OpenAlexfundno aff
Francesco Schettini, Olga Martínez‐Sáez, Claudette Falato, Irene De Santo, Benedetta Conte, Isabel García-Fructuoso, R. Gomez-Bravo, Elia Seguí, Núria Chic, Fara Brasó‐Maristany, Laia Paré, María Vidal, Bárbara Adamo, Montserrat Muñoz-Mateu, Tomás Pascual, Eva Ciruelos, Charles M. Perou, Lisa A. Carey, Aleix Prat

Bibliographic record

VenueESMO Open · 2023
Typereview
Languageen
FieldBiochemistry, Genetics and Molecular Biology
TopicBreast Cancer Treatment Studies
Canadian institutionsnot available
FundersGenentechEuropean Society for Medical OncologyAstellas PharmaOncolytics BiotechSvenska Sällskapet för Medicinsk ForskningGilead SciencesEisaiDaiichi Sankyo EuropeSanofiCelgeneG1 TherapeuticsInstituto de Salud Carlos IIIAmgenPfizerAstraZenecaEli Lilly and Company
KeywordsMetastatic breast cancerMeta-analysisBreast cancerOncologyHormone receptorInternal medicineMedicineValue (mathematics)CancerStatisticsMathematics

Abstract

fetched live from OpenAlex

Background In hormone receptor-positive (HoR+) breast cancer (BC), gene expression analysis identifies luminal A (LumA), luminal B (LumB), human epidermal growth factor receptor 2 (HER2)-enriched (HER2-E), basal-like (BL) intrinsic subtypes and a normal-like group. This classification has an established prognostic value in early-stage HoR+ BC. Here, we carried out a trial-level meta-analysis to determine the prognostic ability of subtypes in metastatic BC (MBC). Materials and methods We systematically reviewed all the available prospective phase II/III trials in HoR+ MBC where subtype was assessed. The primary endpoint was progression-free survival (PFS)/time to progression (TTP) of the LumA subtype compared to non-LumA. Secondary endpoints were PFS/TTP of each individual subtype, according to treatment, menopausal and HER2 status and overall survival (OS). The random-effect model was applied, and heterogeneity assessed through Cochran's Q and I 2 . Threshold for significance was set at P < 0.05. The study was registered in PROSPERO (ID: CRD42021255769). Results Seven studies were included (2536 patients). Non-LumA represented 55.2% and was associated with worse PFS/TTP than LumA [hazard ratio (HR) 1.77, P < 0.001, I 2 = 61%], independently of clinical HER2 status [ P subgroup difference ( P sub ) = 0.16], systemic treatment ( P sub = 0.96) and menopausal status ( P sub = 0.12). Non-LumA tumors also showed worse OS (HR 2.00, P < 0.001, I 2 = 65%), with significantly different outcomes for LumB (PFS/TTP HR 1.46; OS HR 1.41), HER2-E (PFS/TTP HR 2.39; OS HR 2.08) and BL (PFS/TTP HR 2.67; OS HR 3.26), separately (PFS/TTP P sub = 0.01; OS P sub = 0.005). Sensitivity analyses supported the main result. No publication bias was observed. Conclusions In HoR+ MBC, non-LumA disease is associated with poorer PFS/TTP and OS than LumA, independently of HER2, treatment and menopausal status. Future trials in HoR+ MBC should consider this clinically relevant biological classification.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame machine prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.

metaresearch head score (Codex)0.008
metaresearch head score (Gemma)0.019
Version: metacan-v3-hybrid-931329e0061cValidation status: machine_predicted_unvalidated
Candidate categoriesnone
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Meta-analysis · Consensus signal: Meta-analysis
GenreCandidate signal: Review · Consensus signal: Review
Teacher disagreement score0.012
Threshold uncertainty score0.042

Distilled classifier scores by category (both heads)

CategoryCodexGemma
Metaresearch0.0080.019
Meta-epidemiology (narrow)0.0020.001
Meta-epidemiology (broad)0.0120.022
Bibliometrics0.0050.007
Science and technology studies0.0000.001
Scholarly communication0.0020.001
Open science0.0020.001
Research integrity0.0010.001
Insufficient payload (model declined to judge)0.0030.000

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.058
GPT teacher head0.365
Teacher spread0.307 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.

The models applied no category: nothing in the taxonomy fit this work.
Study designMeta-analysis
Domainnot available
GenreReview

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations17
Published2023
Admission routes1
Has abstractyes

Explore more

Same venueESMO OpenSame topicBreast Cancer Treatment StudiesFrench-language works237,207